<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02452034</url>
  </required_header>
  <id_info>
    <org_study_id>5592-097</org_study_id>
    <secondary_id>2014-002807-10</secondary_id>
    <secondary_id>MK-5592-097</secondary_id>
    <nct_id>NCT02452034</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics of Intravenous and Oral Posaconazole in Immunocompromised Children (MK-5592-097)</brief_title>
  <official_title>A Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous (IV) and Powder for Oral Suspension Formulations of Posaconazole (POS) in Immunocompromised Pediatric Subjects With Neutropenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the pharmacokinetics of posaconazole (POS) administered
      intravenously (IV) or orally to immunocompromised pediatric participants.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 7, 2015</start_date>
  <completion_date type="Anticipated">September 10, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 18, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) for POS</measure>
    <time_frame>Any day from Day 7 to Day 10 of therapy for each formulation at pre-dose and 4, 6, 8, 12, 24 hours post-infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) for POS</measure>
    <time_frame>Any day from Day 7 to Day 10 of therapy for each formulation at pre-dose and 4, 6, 8, 12, 24 hours post-infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimum plasma concentration (Cmin) for POS</measure>
    <time_frame>Any day from Day 7 to Day 10 of therapy for each formulation at pre-dose and 4, 6, 8, 12, 24 hours post-infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Average steady-state plasma concentration (Cavg) for POS</measure>
    <time_frame>Any day from Day 7 to Day 10 of therapy for each formulation at pre-dose and 4, 6, 8, 12, 24 hours post-infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of maximum plasma concentration (Tmax) for POS</measure>
    <time_frame>Any day from Day 7 to Day 10 of therapy for each formulation at pre-dose and 4, 6, 8, 12, 24 hours post-infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total body clearance (CL) for POS</measure>
    <time_frame>Any day from Day 7 to Day 10 of therapy for each formulation at pre-dose and 4, 6, 8, 12, 24 hours post-infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent total body clearance (CL/F) for POS</measure>
    <time_frame>Any day from Day 7 to Day 10 of therapy for each formulation at pre-dose and 4, 6, 8, 12, 24 hours post-infusion</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Neutropenia</condition>
  <arm_group>
    <arm_group_label>Young Children 3.5 mg/kg POS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children 2 to less than 7 years of age will receive POS at 3.5 mg/kg by intravenous (IV) solution twice on Day 1, then once daily on Days 2-10. This will be followed by treatment with 3.5 mg/kg POS once daily by powder for oral suspension (PFS) for a minimum of 10 days; or, if they are unwilling or unable to tolerate POS PFS, continued treatment with POS IV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Young Children 4.5 mg/kg POS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children 2 to less than 7 years of age will receive POS at 4.5 mg/kg by IV solution twice on Day 1, then once daily on Days 2-10. This will be followed by treatment with 4.5 mg/kg POS once daily by PFS for a minimum of 10 days; or, if they are unwilling or unable to tolerate POS PFS, continued treatment with POS IV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Older Children 3.5 mg/kg POS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children 7 to 17 years of age will receive POS at 3.5 mg/kg by IV solution twice on Day 1, then once daily on Days 2-10. This will be followed by treatment with 3.5 mg/kg POS once daily by PFS for a minimum of 10 days; or, if they are unwilling or unable to tolerate POS PFS, continued treatment with POS IV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Older Children 4.5 mg/kg POS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children 7 to 17 years of age will receive POS at 4.5 mg/kg by IV solution twice on Day 1, then once daily on Days 2-10. This will be followed by treatment with 4.5 mg/kg POS once daily by PFS for a minimum of 10 days; or, if they are unwilling or unable to tolerate POS PFS, continued treatment with POS IV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Young Children 6 mg/kg POS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children 2 to less than 7 years of age will receive POS at 6 mg/kg by IV solution twice on Day 1, then once daily on Days 2-10. This will be followed by treatment with 6 mg/kg POS once daily by PFS for a minimum of 10 days; or, if they are unwilling or unable to tolerate POS PFS, continued treatment with POS IV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Older Children 6 mg/kg POS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children 7 to 17 years of age will receive POS at 6 mg/kg by IV solution twice on Day 1, then once daily on Days 2-10. This will be followed by treatment with 6 mg/kg POS once daily by PFS for a minimum of 10 days; or, if they are unwilling or unable to tolerate POS PFS, continued treatment with POS IV.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Posaconazole IV solution</intervention_name>
    <description>Posaconazole 300 mg IV solution (sterile)</description>
    <arm_group_label>Young Children 3.5 mg/kg POS</arm_group_label>
    <arm_group_label>Young Children 4.5 mg/kg POS</arm_group_label>
    <arm_group_label>Older Children 3.5 mg/kg POS</arm_group_label>
    <arm_group_label>Older Children 4.5 mg/kg POS</arm_group_label>
    <arm_group_label>Young Children 6 mg/kg POS</arm_group_label>
    <arm_group_label>Older Children 6 mg/kg POS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Posaconazole powder for oral suspension</intervention_name>
    <description>Posaconazole 300 mg powder for oral suspension</description>
    <arm_group_label>Young Children 3.5 mg/kg POS</arm_group_label>
    <arm_group_label>Young Children 4.5 mg/kg POS</arm_group_label>
    <arm_group_label>Older Children 3.5 mg/kg POS</arm_group_label>
    <arm_group_label>Older Children 4.5 mg/kg POS</arm_group_label>
    <arm_group_label>Young Children 6 mg/kg POS</arm_group_label>
    <arm_group_label>Older Children 6 mg/kg POS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have documented or anticipated neutropenia expected to last for at least 7 days,
             following treatment in at least one of the following clinical situations: acute
             leukemia, myelodysplasia, severe aplastic anemia, recipients of Autologous
             hematopoietic stem cell transplant (HSCT), high risk neuroblastoma, advanced stage
             non-Hodgkin's lymphoma, hemophagocytic lymphohistiocytosis

          -  Have a central line in place prior to IV study therapy

          -  Participants of reproductive potential agree to remain abstinent, or use a medically
             accepted method of birth control

        Exclusion Criteria:

          -  Has a proven or probable invasive fungal infection

          -  Has received any formulation of POS within prior 10 days

          -  Is receiving any prohibited drugs

          -  Has laboratory results that are outside of normal limits at screening, as follows: a)
             Moderate or severe liver dysfunction, as defined as: Aspartate aminotransferase (AST)
             &gt; 5 times the upper limit of normal (ULN), OR Alanine aminotransferase (ALT) &gt; 5 times
             the ULN, OR Serum total bilirubin &gt;2.5 times the ULN, OR AST or ALT &gt; 3 times ULN with
             total bilirubin &gt; 2 times ULN; b) Calculated creatinine clearance &lt;30 mL/min.

          -  Has QTc (QT interval corrected for rate) prolongation defined as: a) Symptomatic QTc
             prolongation &gt;450 msec (males) or &gt;470 msec (females) OR b) Any QTc prolongation of
             &gt;500 msec

          -  Is pregnant, intends to become pregnant during study, or is breastfeeding

          -  Has a history of anaphylaxis attributed to the azole class of antifungal agents

          -  Is not expected to receive a minimum of 10 days of POS IV solution

          -  Has participated in any Phase 1 Investigational New Drug (IND) study within prior 30
             days or expects to do so within the following 60 days

          -  Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling or
             child) who is investigational site or sponsor staff directly involved with this trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0118)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1447</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0035)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0031)</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MSD Belgium BVBA/SPRL</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erik Antonissen</last_name>
      <phone>32 27766501</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD SRO Czechýýýýýýýýýýýýýýý</name>
      <address>
        <city>Prague</city>
        <zip>Prague 6</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas J. Johansson</last_name>
      <phone>420 233 010 111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme</name>
      <address>
        <city>Glostrup</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrin Moeschlin</last_name>
      <phone>46857813545</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD Sharp &amp; Dohme GmbH</name>
      <address>
        <city>Haar</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>German Medical Information Center</last_name>
      <phone>49 800 673 673 673</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD CARD</name>
      <address>
        <city>Guatemala</city>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edgar R Hernandez</last_name>
      <phone>502 24979595</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD Italia S.r.l.</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paola Chiaretta Fattore</last_name>
      <phone>39 0636191739</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD Norge A/S</name>
      <address>
        <city>Drammen</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrin Moeschlin</last_name>
      <phone>46857813545</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp and Dohme de Espana S.A.</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lourdes Lopez-Bravo</last_name>
      <phone>(0034) 913210654</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD Sweden</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrin Moeschlin</last_name>
      <phone>46857813545</phone>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Guatemala</country>
    <country>Italy</country>
    <country>Norway</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Thailand</country>
  </removed_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2015</study_first_submitted>
  <study_first_submitted_qc>May 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2015</study_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Posaconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

